CN114965802A - Quality control method of climacteric syndrome-relieving tablet - Google Patents
Quality control method of climacteric syndrome-relieving tablet Download PDFInfo
- Publication number
- CN114965802A CN114965802A CN202111524789.7A CN202111524789A CN114965802A CN 114965802 A CN114965802 A CN 114965802A CN 202111524789 A CN202111524789 A CN 202111524789A CN 114965802 A CN114965802 A CN 114965802A
- Authority
- CN
- China
- Prior art keywords
- fingerprint
- solution
- methanol
- retention time
- mobile phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 25
- 238000003908 quality control method Methods 0.000 title description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 114
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000001514 detection method Methods 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 20
- JAYVHSBYKLLDJC-DSNJPTTOSA-N (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C=C(O)C=C1\C=C\C1=CC=C(O)C=C1 JAYVHSBYKLLDJC-DSNJPTTOSA-N 0.000 claims abstract description 19
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000010828 elution Methods 0.000 claims abstract description 14
- 239000013558 reference substance Substances 0.000 claims abstract description 14
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 9
- 239000000945 filler Substances 0.000 claims abstract description 7
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 7
- 238000004458 analytical method Methods 0.000 claims abstract description 3
- 230000014759 maintenance of location Effects 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 24
- 238000005303 weighing Methods 0.000 claims description 23
- 239000012085 test solution Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000012088 reference solution Substances 0.000 claims description 12
- 238000001228 spectrum Methods 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 9
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- KVRQGMOSZKPBNS-FMHLWDFHSA-N Harpagoside Chemical compound O([C@@H]1OC=C[C@@]2(O)[C@H](O)C[C@]([C@@H]12)(C)OC(=O)\C=C\C=1C=CC=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KVRQGMOSZKPBNS-FMHLWDFHSA-N 0.000 claims description 6
- KVRQGMOSZKPBNS-BYYMOQGZSA-N Harpagoside Natural products C[C@@]1(C[C@@H](O)[C@@]2(O)C=CO[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]12)OC(=O)C=Cc4ccccc4 KVRQGMOSZKPBNS-BYYMOQGZSA-N 0.000 claims description 6
- WUOIMLIHAHOCCR-UHFFFAOYSA-N curculigoside Natural products COc1ccc(OC2OC(CO)C(O)C(O)C2O)c(OC)c1C(=O)OCc3cc(O)ccc3OC4OC(CO)C(O)C(O)C4O WUOIMLIHAHOCCR-UHFFFAOYSA-N 0.000 claims description 6
- SJJRKHVKAXVFJQ-UHFFFAOYSA-N curculigoside I Natural products COC1=CC=CC(OC)=C1C(=O)OCC1=CC(O)=CC=C1OC1C(O)C(O)C(O)C(CO)O1 SJJRKHVKAXVFJQ-UHFFFAOYSA-N 0.000 claims description 6
- SJJRKHVKAXVFJQ-QKYBYQKWSA-N curculigoside a Chemical compound COC1=CC=CC(OC)=C1C(=O)OCC1=CC(O)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SJJRKHVKAXVFJQ-QKYBYQKWSA-N 0.000 claims description 6
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 claims description 6
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 22
- 239000000047 product Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 230000001502 supplementing effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 4
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 4
- 244000292697 Polygonum aviculare Species 0.000 description 4
- 235000006386 Polygonum aviculare Nutrition 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 240000001341 Reynoutria japonica Species 0.000 description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000234276 Curculigo Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000081426 Ranunculus ficaria Species 0.000 description 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- YBZZAVZIVCBPDJ-UHFFFAOYSA-N schizandrin B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)(O)CC2=CC2=C1OCO2 YBZZAVZIVCBPDJ-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
- G01N30/8686—Fingerprinting, e.g. without prior knowledge of the sample components
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Library & Information Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to medicine detection, in particular to a high performance liquid chromatography fingerprint of a climacteric syndrome tablet and establishment of the fingerprint. The reference substance adopted by the detection method is 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside, and the high performance liquid chromatography analysis is carried out, wherein the chromatographic conditions are that octadecylsilane chemically bonded silica is used as a filling agent; the detection wavelength is 260-296 nm; taking methanol as mobile phase A and 0.1% phosphoric acid solution as mobile phase B, performing gradient elution at flow rate of 0.8-1.2ml/min and column temperature of 20-30 deg.C. The method can ensure the stability, consistency and controllability of the quality of the traditional Chinese medicine tablet, thereby ensuring the safety and effectiveness of the medicine.
Description
Technical Field
The invention relates to the field of medicine detection, in particular to a quality control method of a climacteric syndrome relieving tablet, and more particularly relates to high performance liquid chromatography fingerprint detection and fingerprint establishment of the climacteric syndrome relieving tablet.
Background
The climacteric syndrome relieving medicine is prepared with 15 kinds of Chinese medicinal materials including fleeceflower root, vine of multiflower knotweed, prepared rehmannia root, schisandra, oriental water plantain rhizome, tree peony bark, hooked uncaria, figwort, tuckahoe, curculigo rhizome, ophiopogon root, light wheat, magnetite, nacre and other material and through decoction, diacolation, concentration and other steps. The existing quality detection standard aims at the content of emodin to evaluate the quality of gengnian An, but the prepared polygonum multiflorum and the vine of multiflower knotweed in the prescription are two medicines which play a main role in gengnian An. The effective components of the two are 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside. There have been studies on the determination of the contents of 6 active ingredients in climacteric-syndrome for both (HPLC-DAD method for simultaneously determining the contents of 6 active ingredients in climacteric-syndrome, application method, etc., drug analysis of impurities 2012,32(1)), but this method employs 6 detection wavelengths for the 6 ingredients to measure separately, and is complicated.
The traditional Chinese medicine fingerprint is a comprehensive and quantifiable traditional Chinese medicine quality control means established on the basis of the research of a traditional Chinese medicine chemical component system, can describe and evaluate the quality of the traditional Chinese medicine on the whole, and has the characteristics of large information amount, strong characteristics, integrity and the like. At the present stage, under the condition that most of the effective components of the traditional Chinese medicine are not clear, the fingerprint spectrum can comprehensively reflect the relative relationship of the chemical components contained in the medicine, reflects the complexity and the correlation of the components of the traditional Chinese medicine, is adaptive to the traditional theory of the traditional Chinese medicine, can really and effectively characterize, comprehensively evaluate and comprehensively control the internal quality of the traditional Chinese medicine, and has important significance for effectively controlling the quality of the traditional Chinese medicine or the Chinese patent medicine.
Disclosure of Invention
The invention provides a fingerprint spectrum measuring method of climacteric syndrome relieving tablets, which can ensure the stability, consistency and controllability of the quality of the traditional Chinese medicine tablets, thereby ensuring the safety and effectiveness of the medicine.
In order to achieve the above object, the present invention provides a method for measuring a fingerprint of a climacteric syndrome tablet, comprising the steps of:
(1) preparation of reference solutions
Precisely weighing 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside reference substance, and dissolving in methanol to obtain reference solution;
(2) preparation of test solution
Removing coating from the climacteric syndrome relieving tablet, grinding, adding methanol solution, heating under reflux, and filtering to obtain filtrate.
(3) Measurement of
And sucking the reference substance solution and the test solution, and performing high performance liquid chromatography, wherein the chromatographic conditions are as follows:
octadecylsilane chemically bonded silica is used as a filling agent; the detection wavelength is 260-296 nm; taking methanol as mobile phase A and 0.1% phosphoric acid solution as mobile phase B, performing gradient elution at flow rate of 0.8-1.2ml/min and column temperature of 20-30 deg.C.
In one embodiment of the fingerprint determination method of the present invention, wherein the gradient program in step (3) is:
in one embodiment of the fingerprint measuring method of the present invention, the detection wavelength in the step (3) is 270 nm.
In one embodiment of the fingerprint measuring method of the present invention, the column temperature in the step (3) is 20 ℃.
The invention also provides a climacteric syndrome tablet fingerprint spectrum establishing method, which comprises the following steps:
(1) preparation of reference solutions
Accurately weighing 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside reference substance, and dissolving in methanol to obtain reference solution;
(2) preparation of test solution
Removing coating from the climacteric tablet, grinding, adding methanol solution, heating under reflux, filtering, and collecting the filtrate.
(3) Obtaining a chromatogram
And sucking the reference substance solution and the test solution, and performing high performance liquid chromatography, wherein the chromatographic conditions are as follows:
octadecylsilane chemically bonded silica is used as a filling agent; the detection wavelength is 260-296 nm; using methanol as mobile phase A and 0.1% phosphoric acid solution as mobile phase B, performing gradient elution at flow rate of 0.8-1.2ml/min and column temperature of 20-30 deg.C, and performing the following gradient:
(4) generating a comparison fingerprint
Selecting qualified chromatograms of a plurality of batches of the climacteric syndrome tablets, and taking a 2,3,5,4 '-tetrahydroxystilbene-2-O-beta-D-glucoside peak as a reference peak to obtain 10 maps with common peaks, wherein the retention time of the 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside is 55.2min, the retention time of harpagoside is 92.2min, the retention time of schisandrin is 101.5min, the retention time of deoxyschizandrin is 122.6min, the retention time of schisandrin is 128.1min, the retention time of curculigoside is 56.9min, and the relative retention time of the 10 common peaks is as follows:
in one embodiment of the present invention, the climacteric syndrome fingerprint establishing method, wherein the detection wavelength in step (3) is 270 nm.
In a specific embodiment of the climacteric syndrome tablet fingerprint spectrum establishing method, the column temperature in the step (3) is 20 ℃.
The invention establishes a fingerprint spectrum detection method of the preparation aiming at the problems of various medicinal herbs, complex components and difficulty in comprehensively reflecting the comprehensive information of the medicine by qualitative and quantitative analysis of individual components, so as to better and more effectively control the quality of the climacteric syndrome treating tablet.
Drawings
FIG. 1: finger print using mobile phase system 1
FIG. 2: finger print using mobile phase system 2
FIG. 3: finger print using mobile phase system 3
FIG. 4: finger print using mobile phase system 4
FIG. 5: finger print using mobile phase system 5
FIG. 6: fingerprint obtained by ultrasonic extraction or reflux extraction of test sample
FIG. 7: fingerprint obtained under different extraction solvents
FIG. 8: finger print at different column temperatures
FIG. 9: fingerprint for collecting chromatographic information within 140min
FIGS. 10-1 to 10-6 are fingerprints of 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside, harpagoside, schizandrin A, schizandrin B and curculigoside as reference substances for component identification, respectively.
FIGS. 10-7: test sample map
FIG. 11: and (4) fitting multiple batches of samples to the generated control fingerprints.
Detailed Description
EXAMPLE 1 selection of detection wavelength
Firstly, a DAD detector is adopted to detect a sample to be detected, the chromatographic peak information of the sample is inspected, and the detection wavelength is screened.
Preparation of a test solution: taking 20 tablets of the product, removing the coating, grinding, taking 3g, precisely weighing, placing in a conical flask with a plug, precisely adding 25ml of 75% methanol, sealing the plug, weighing, carrying out ultrasonic treatment (power 250W and frequency 40kHz) for 30 minutes, cooling, weighing again, supplementing the weight loss with 75% methanol, shaking up, filtering, and taking the subsequent filtrate to obtain the product.
By usingODS-4 column, column temperature 30 deg.C, flow rate 0.8ml/min, acetonitrile as mobile phase A, aqueous solution as mobile phase B, gradient elution was performed as follows. Injecting sample 10ul, collecting time 150min,
the prescription of climacteric syndrome-relieving tablet contains 12 medicinal materials of rehmannia root, vine of multiflower knotweed, prepared fleece-flower root, etc., and its quality control components are vine of multiflower knotweed and prepared fleece-flower root, respectively, and their maximum absorption is 270-330 nm. The sample has rich chromatographic absorption in the wave band of 260nm-296nm, and compared with chromatographic peak conditions of the sample at 260nm, 270nm, 280nm and 296nm, the information content of the 270nm fingerprint spectrum is more, so that the chemical components of the product can be more fully embodied, the baseline drift is not large, the other medicinal material components have absorption at 270nm, and 270nm is selected as the detection wavelength.
Example 2 mobile phase System selection
Preparation of a test solution: taking 20 tablets of the product, removing the coating, grinding, taking 3g, precisely weighing, placing in a conical flask with a plug, precisely adding 25ml of 75% methanol, sealing the plug, weighing, carrying out ultrasonic treatment (power 250W and frequency 40kHz) for 30 minutes, cooling, weighing again, supplementing the weight loss with 75% methanol, shaking up, filtering, and taking the subsequent filtrate to obtain the product.
By usingODS-4 column (250 mm. times.4.6 mm, 5 μm) was tested by examining acetonitrile-0.05% phosphoric acid solution, methanol-0.1% phosphoric acid solution and the like.
(1) The system 1:
acetonitrile is used as mobile phase A, 0.05% phosphoric acid solution is used as mobile phase B, the collection time is 50min, the elution gradient is shown in the following table, and the result is shown in figure 1.
(2) And (3) system 2: acetonitrile is used as mobile phase A, 0.05% phosphoric acid solution is used as mobile phase B, the collection time is 140min, the elution gradient is shown in the following table, and the result is shown in figure 2.
(3) And (3) system: methanol is used as mobile phase A, 0.1% phosphoric acid solution is used as mobile phase B, the collection time is 140min, the elution gradient is shown in the following table, and the result is shown in figure 3.
(4) And (4) system: methanol is used as mobile phase A, 0.1% phosphoric acid solution is used as mobile phase B, the collection time is 140min, the elution gradient is shown in the following table, and the result is shown in figure 4.
(5) And (5) the system: methanol is used as mobile phase A, 0.1% phosphoric acid solution is used as mobile phase B, the collection time is 140min, the elution gradient is shown in the following table, and the result is shown in figure 5.
As can be seen from the above experiment, the methanol-0.1% phosphoric acid solution system (system 5) has the best separation effect on the chromatographic peak of the test solution of the climacteric syndrome tablet, the peak shape is good, the base line is stable, and the required separation degree is achieved.
Example 3 examination of extraction mode
Taking 20 tablets of the product, removing the coating, grinding, taking 3g, precisely weighing, placing in a conical flask with a plug, precisely adding 20ml of methanol, sealing the plug, weighing, carrying out ultrasonic treatment (power 250W and frequency 40kHz) for 1 hour, cooling, weighing again, supplementing the weight loss by using methanol, shaking up, filtering, and taking the subsequent filtrate.
Taking 20 tablets of the product, removing the coating, grinding, taking 3g, precisely weighing, placing in a conical flask with a plug, precisely adding 20ml of methanol, sealing the plug, weighing, heating and refluxing for 1 hour, cooling, weighing again, supplementing the lost weight with methanol, shaking uniformly, filtering, and taking the subsequent filtrate.
Measuring by high performance liquid chromatography (China pharmacopoeia 2020 edition four-part general regulation 0512).
Octadecylsilane chemically bonded silica is used as filler (ODS-4 column, 250mm in length, 4.6mm in inner diameter, S/N7 AF37032), using methanol as mobile phase A and 0.1% phosphoric acid solution as mobile phase B, and performing gradient elution according to the following table; the flow rate is 1.0 ml/min; the detection wavelength is 270 nm; the column temperature was 25 ℃.
Precisely sucking 10 μ l of each sample solution, injecting into liquid chromatograph, and measuring. The results are shown in the following table and FIG. 6.
As can be seen from the above table, when the reflux extraction is adopted, the amount of the obtained fingerprint information is large, and the peak response value is large, so the reflux extraction is adopted.
Example 4 extraction solvent examination
Taking 20 tablets of the product, removing the coating, grinding, taking 3g, precisely weighing, placing in a conical flask with a plug, precisely adding 20ml of water, 25% methanol, 50% methanol, 75% methanol, methanol and absolute ethanol respectively, sealing the plug, weighing, heating and refluxing for 1 hour, cooling, weighing again, supplementing the lost weight with water, 25% methanol, 50% methanol, 75% methanol, methanol and absolute ethanol respectively, shaking up, filtering, and taking the subsequent filtrate to obtain the product.
The measurement method was the same as in example 3. The results are shown in the following table, FIG. 7.
EXAMPLE 5 examination of column temperature
In the chromatographic fingerprint detection, the column temperature usually affects the separation effect, and the inventor analyzes the fingerprint of the test solution of the climacteric syndrome tablet under the three column temperature conditions of 20 ℃, 25 ℃ and 30 ℃. Other conditions were as in example 8. The result shows that the chromatographic peak separation effect is good and the baseline is stable at 20 ℃, so the column temperature at the time of detection is optimally selected to be 20 ℃. See fig. 8.
Example 6 chromatographic information acquisition time determination
The reference solution and the test solution were prepared as in example 8. In order to investigate the chromatographic information acquisition time, the product is detected under the following chromatographic conditions: the chromatographic column is as follows:ODS-4 column (250 mm. times.4.6 mm, 5 μm); the detection wavelength is 270 nm; the column temperature is 20 ℃; the flow rate is 1.0 ml/min; the sample amount is 10 mul; mobile phase: gradient elution was performed according to the following table using methanol as mobile phase a and 0.1% phosphoric acid solution as mobile phase B. The result is shown in figure 9, no chromatographic peak is present after 140min, so only the chromatographic information within 140min is collected.
EXAMPLE 7 selection of reference
The reference solution and the sample solution were prepared and the chromatographic conditions were the same as in example 8. According to the chemical components contained in the medicinal materials of GENGNIANAN tablet, 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside, harpagoside, schizandrin, deoxyschizandrin, schisandrin B and curculigoside are selected as reference substances for component confirmation, and the results are shown in figures 10-1 to 10-7.
As can be seen from comparison of the test sample fingerprint and the control sample fingerprint, the retention time of 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside is 55.2min, the retention time of harpagoside is 92.2min, the retention time of schizandrol A is 101.5min, the retention time of deoxyschizandrin is 122.6min, the retention time of schisandrin B is 128.1min, and the retention time of curculigoside is 56.9 min. The ratio of the peak area of the 2,3,5,4 '-tetrahydroxystilbene-2-O-beta-D-glucoside chromatographic peak in the fingerprint of the test sample is relatively large, and the result of the actual measurement of a plurality of samples shows that the peak area is relatively stable, so that the 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside is selected as a reference peak and is used as a reference object of the climacteric syndrome fingerprint.
Example 8 Gengnian comparison fingerprint establishment
Preparation of reference solutions: accurately weighing 10mg of 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside reference substance, placing the reference substance in a 200ml brown measuring flask, adding methanol to dissolve and dilute the reference substance to a scale, and shaking up to obtain the product. (50. mu.g of solution per 1 ml)
Preparation of a test solution: taking 20 tablets of the product, removing the coating, grinding, taking 3g, precisely weighing, placing in a conical flask with a plug, precisely adding 20ml of methanol, sealing the plug, weighing, heating and refluxing for 30 minutes, cooling, weighing again, supplementing the lost weight with methanol, shaking uniformly, filtering, and taking the subsequent filtrate.
Chromatographic conditions and system applicability test: measuring by high performance liquid chromatography (China pharmacopoeia 2020 edition four-part general regulation 0512). Octadecylsilane chemically bonded silica was used as a filler (column:ODS-4250 mm. times.4.6 mm, 5 μm); the detection wavelength is 270 nm; the column temperature is 20 ℃; the flow rate is 1.0 ml/min; gradient elution was performed according to the following table using methanol as mobile phase a and 0.1% phosphoric acid solution as mobile phase B. The number of theoretical plates is not less than 10000 in terms of 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside peak. Are respectively provided withPrecisely sucking 10 μ l of each of the reference solution and the sample solution, injecting into a liquid chromatograph, measuring, and recording chromatogram for 140 minutes.
The batch numbers of 201101, 201102, 201103, 201104, 201201, 201202, 201203, 201204, 201205 and 201206 climacteric syndrome tablets produced by Yabao pharmaceutical industry group Limited company are respectively detected according to the established fingerprint spectrum measuring method, a national pharmacopoeia Committee's traditional Chinese medicine chromatogram fingerprint spectrum similarity evaluation system' (version 2012.130723) is adopted to fit and generate a comparison fingerprint spectrum, which is shown in figure 11, and 2,3,5,4 '-tetrahydroxy stilbene-2-O-beta-D-glucoside peak is taken as a reference peak to obtain 10 spectrums with common peaks, wherein the retention time of 2,3,5,4' -tetrahydroxy stilbene-2-O-beta-D-glucoside is 55.2min, the retention time of harpagoside is 92.2min, the retention time of schisandrin is 101.5min, the retention time of deoxyschizandrin is 122.6min, and the retention time of schisandrin is 122.6min, The retention time of schisandrin B is 128.1min, the retention time of curculigoside is 56.9min, and the relative retention time of 10 common peaks is as follows:
Claims (7)
1. a fingerprint spectrum measuring method of climacteric syndrome-relieving tablets comprises the following steps:
(1) preparation of reference solutions
Precisely weighing 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside reference substance, and dissolving in methanol to obtain reference solution;
(2) preparation of test solution
Taking the climacteric syndrome relieving tablet, removing coating, grinding, adding methanol solution, heating under reflux for extraction, filtering, and collecting filtrate;
(3) measurement of
And sucking the reference substance solution and the test solution, and performing high performance liquid chromatography, wherein the chromatographic conditions are as follows:
octadecylsilane chemically bonded silica is used as a filling agent; the detection wavelength is 260-296 nm; taking methanol as mobile phase A and 0.1% phosphoric acid solution as mobile phase B, performing gradient elution at flow rate of 0.8-1.2ml/min and column temperature of 20-30 deg.C.
3. the fingerprint measuring method according to claim 1, wherein the detection wavelength in said step (3) is 270 nm.
4. The fingerprint measuring method according to claim 1 wherein the column temperature in said step (3) is 20 ℃.
5. A climacteric syndrome tablet fingerprint establishing method comprises the following steps:
(1) preparation of reference solutions
Precisely weighing 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside reference substance, and dissolving in methanol to obtain reference solution;
(2) preparation of test solution
Removing coating from the climacteric tablet, grinding, adding methanol solution, heating under reflux, and filtering to obtain filtrate;
(3) obtaining the chromatogram
And (3) sucking the reference substance solution and the test solution, and performing high performance liquid chromatography analysis under the following chromatographic conditions:
octadecylsilane chemically bonded silica is used as a filling agent; the detection wavelength is 260-296 nm; using methanol as mobile phase A and 0.1% phosphoric acid solution as mobile phase B, performing gradient elution at flow rate of 0.8-1.2ml/min and column temperature of 20-30 deg.C, and performing the following gradient:
(4) generating a comparison fingerprint
Selecting qualified chromatograms of a plurality of batches of the climacteric syndrome tablets, and taking a 2,3,5,4 '-tetrahydroxystilbene-2-O-beta-D-glucoside peak as a reference peak to obtain 10 maps with common peaks, wherein the retention time of the 2,3,5,4' -tetrahydroxystilbene-2-O-beta-D-glucoside is 55.2min, the retention time of harpagoside is 92.2min, the retention time of schisandrin is 101.5min, the retention time of deoxyschizandrin is 122.6min, the retention time of schisandrin is 128.1min, the retention time of curculigoside is 56.9min, and the relative retention time of the 10 common peaks is as follows:
6. the method of establishing a fingerprint according to claim 5 wherein the detection wavelength in step (3) is 270 nm.
7. The fingerprint measuring method according to claim 5 wherein the column temperature in step (3) is 20 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111524789.7A CN114965802B (en) | 2021-12-14 | 2021-12-14 | Quality control method of climacteric syndrome relieving tablet |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111524789.7A CN114965802B (en) | 2021-12-14 | 2021-12-14 | Quality control method of climacteric syndrome relieving tablet |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114965802A true CN114965802A (en) | 2022-08-30 |
CN114965802B CN114965802B (en) | 2024-04-12 |
Family
ID=82974756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111524789.7A Active CN114965802B (en) | 2021-12-14 | 2021-12-14 | Quality control method of climacteric syndrome relieving tablet |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114965802B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116165320A (en) * | 2023-04-21 | 2023-05-26 | 保定市食品药品检验所 | Traditional Chinese medicine fingerprint detection method of blood-nourishing nerve-soothing tablet |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101288700A (en) * | 2007-04-16 | 2008-10-22 | 北京陆尔草医药科技有限公司 | Chinese medicinal composition and preparation method and quality control method thereof |
CN101579422A (en) * | 2009-06-29 | 2009-11-18 | 刘斌 | Measuring method of high-performance liquid chromatogram fingerprint of jiangzhining |
CN107727753A (en) * | 2017-08-31 | 2018-02-23 | 扬子江药业集团有限公司 | Hundred method for building up and its finger-print for finding pleasure in dormancy capsule fingerprint pattern |
-
2021
- 2021-12-14 CN CN202111524789.7A patent/CN114965802B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101288700A (en) * | 2007-04-16 | 2008-10-22 | 北京陆尔草医药科技有限公司 | Chinese medicinal composition and preparation method and quality control method thereof |
CN101579422A (en) * | 2009-06-29 | 2009-11-18 | 刘斌 | Measuring method of high-performance liquid chromatogram fingerprint of jiangzhining |
CN107727753A (en) * | 2017-08-31 | 2018-02-23 | 扬子江药业集团有限公司 | Hundred method for building up and its finger-print for finding pleasure in dormancy capsule fingerprint pattern |
Non-Patent Citations (6)
Title |
---|
侯峰 等: "更年安丸质量标准研究", 辽宁中医杂志, no. 03, 18 March 2013 (2013-03-18) * |
刘振丽 等: "何首乌药材质量评价研究", 中药材, no. 03, 25 March 2007 (2007-03-25) * |
易延逵 等: "更年颗粒"全指纹图谱系"的研究", 中成药, no. 12, 20 December 2008 (2008-12-20) * |
杨慈海 等: "HPLC法测定更年安片中二苯乙烯苷的含量", 中国药师, no. 12, 5 December 2011 (2011-12-05) * |
王桂红 等: "何首乌HPLC指纹图谱研究", 湖北中医学院学报, no. 02, 20 April 2010 (2010-04-20) * |
郭汉文 等: "HPLC双波长法测定更年安胶囊中二苯乙烯苷和五味子醇甲的含量", 西北药学杂志, no. 03, 10 May 2013 (2013-05-10) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116165320A (en) * | 2023-04-21 | 2023-05-26 | 保定市食品药品检验所 | Traditional Chinese medicine fingerprint detection method of blood-nourishing nerve-soothing tablet |
CN116165320B (en) * | 2023-04-21 | 2023-07-21 | 保定市食品药品检验所 | Traditional Chinese medicine fingerprint detection method of blood-nourishing nerve-soothing tablet |
Also Published As
Publication number | Publication date |
---|---|
CN114965802B (en) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105738546B (en) | Method for establishing fingerprint of radix curcumae medicinal material and fingerprint thereof | |
CN102818861A (en) | Quality control method and application of Qingdu Anshen capsule | |
CN103063766B (en) | Construction method of Chinese herbal medicine Naoshuantong preparation high performance liquid chromatography (HPLC) finger-print and application thereof | |
CN114965802A (en) | Quality control method of climacteric syndrome-relieving tablet | |
CN111948330B (en) | Detection method of finger-print of Renzhu stomach-invigorating granules | |
CN110441413B (en) | Construction method and detection method of HPLC fingerprint of Qianbai rhinitis tablets | |
CN109239250B (en) | Method for measuring fingerprint of brain-benefiting heart tablet and standard fingerprint thereof | |
CN102068553B (en) | Method for constructing high performance liquid chromatographic (HPLC) fingerprint of Mammary lump preparation arising from qi stagnation and blood stasis | |
CN109115904B (en) | Construction method and application of UPLC fingerprint of Dingkundan | |
CN114674947B (en) | Detection method for rapidly and comprehensively controlling quality of pinellia tuber magnolia bark Shang Biaozhun decoction | |
CN112285234B (en) | Gas phase fingerprint spectrum analysis method of traditional Chinese medicine | |
CN113759011B (en) | Method for establishing characteristic spectrum of starwort root and preparation thereof | |
CN111220719B (en) | Method for evaluating quality of ginseng medicinal material by using fingerprint spectrum | |
CN110297047B (en) | Establishment method of HPLC fingerprint of lysimachia capillipes hemsl medicinal material and fingerprint thereof | |
CN113640432A (en) | Quality evaluation method of loins strengthening and body building pills | |
CN109781884B (en) | Establishing method of Qianliexin capsule fingerprint and fingerprint thereof | |
CN103575823A (en) | Detection method of 8 chemical components in Tangminling preparation | |
CN108107130B (en) | Method for measuring fingerprint spectrum of Shenzhiling preparation | |
CN111474276B (en) | Quality control method of yang invigorating tablet preparation | |
CN104198634A (en) | Method for establishing Sishen tablet fingerprint spectrum | |
CN105486764B (en) | A kind of analysis method and its application of the gas-phase fingerprint pattern of female clever ball | |
CN114166958B (en) | Detection method of fingerprint of traditional Chinese medicine compound herba xanthil stomach-calming particles and application thereof | |
CN112268968B (en) | Detection method of fingerprint spectrum of medicinal preparation | |
CN113884595B (en) | Method for determining fingerprint of XiaoMing decoction reference sample | |
CN113219095B (en) | Construction method of fingerprint of Fukean tablet and fingerprint thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |